In this article, we will list the 5 Best Performing NASDAQ Stocks According to Wall Street Analysts. Please visit 10 Best Performing NASDAQ Stocks According to Wall Street Analysts to see the extended list and the methodology behind it.

5. Climb Bio Inc. (NASDAQ:CLYM)

6-Month Performance: 379.39%

Average Upside Potential: 69.49%

Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement expected to yield approximately $110 million in gross proceeds. The financing involves the sale of 9,481,000 shares of common stock at $9.50 per share, along with pre-funded warrants for an additional 2,106,000 shares.

The offering saw significant participation from a mix of new and existing institutional investors, including RA Capital Management, Adage Capital Partners, and Cormorant Asset Management. Leerink Partners and Piper Sandler served as the lead placement agents for the deal. As part of the agreement, the company committed to filing a registration statement with the SEC within 45 days of closing to allow for the resale of these securities.

While the specific use of proceeds was not detailed in the announcement, the capital injection strengthens Climb Bio Inc.’s (NASDAQ:CLYM) financial position as it advances its therapeutic pipeline. The shares and warrants were issued via a private placement exempt from standard registration requirements under the Securities Act of 1933.

Climb Bio Inc. (NASDAQ:CLYM) is a clinical-stage biotech company focused on developing therapies for immune-mediated diseases, with a pipeline centered on monoclonal antibodies targeting B-cell-driven conditions.

4. Damora Therapeutics Inc. (NASDAQ:DMRA)

6-Month Performance: 254.69%

Average Upside Potential: 70.29%

Damora Therapeutics Inc. (NASDAQ:DMRA) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 23, Damora Therapeutics appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30. Jarrett, who will also join the Board of Directors, previously served as COO and CFO at Arcus Biosciences and held executive roles at Uber and Medivation. Her background in oncology drug development and investment banking is expected to accelerate the development of DMR-001, the company’s lead program for mutant calreticulin-driven blood disorders.

In addition to the new CEO, the company has expanded its Board of Directors with the appointments of Dr. Cameron Turtle and Mike Landsittel. Dr. Turtle currently serves as CEO of Spyre Therapeutics, while Landsittel is the former CFO of Blueprint Medicines. Simultaneously, Peter Harwin, a founding partner at Fairmount Funds Management, has been named Chairman of the Board, succeeding departing directors Dr. Carl Goldfischer, Dr. Jayson Dallas, and Amit Munshi.

These leadership changes follow the recent transaction between Damora and Galecto, signaling a strategic shift toward rapid clinical advancement and commercial readiness. The new team will oversee a portfolio aimed at redefining care for myeloproliferative neoplasms. With a reinforced board and executive leadership, the company plans to leverage its strong balance sheet to advance its pipeline assets and deliver value to shareholders.

Damora Therapeutics Inc. (NASDAQ:DMRA) is a biotech company focused on redefining care for hematologic disorders. The company is advancing a new generation of biologics targeting mutant calreticulin-driven myeloproliferative neoplasms, such as essential thrombocythemia and myelofibrosis.

3. Immix Biopharma Inc. (NASDAQ:IMMX)

6-Month Performance: 155.18%

Average Upside Potential: 83.05%

Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regulatory approval for NXC-201. This therapy targets relapsed/refractory AL Amyloidosis, a condition where the immune system produces toxic proteins that cause organ failure. Topline results from the 40-patient study are expected in Q3 2026, which will be followed by a BLA submission and a planned commercial launch.

NXC-201 is a specialized CAR-T cell therapy designed to eliminate the source of toxic light chains in patients. The treatment has already received several high-priority regulatory labels, including Breakthrough Therapy and Orphan Drug designations from the FDA and EMA. If successful, it would become the first FDA-approved treatment specifically for the relapsed/refractory stage of this disease.

To lead the upcoming regulatory and commercial phases, the company appointed Dr. Richard Graydon as Chief Medical Officer. Dr. Graydon brings extensive experience from Merck and Johnson & Johnson, where he oversaw the approval of major oncology drugs like Keytruda and Darzalex. His expertise is expected to be vital as Immix Biopharma Inc. (NASDAQ:IMMX) transitions from a clinical-stage company to a commercial entity following the anticipated BLA filing.

Immix Biopharma Inc. (NASDAQ:IMMX) is a clinical-stage biotechnology company focused on treating relapsed/refractory AL Amyloidosis. Its lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy designed to eliminate the source of toxic light chains that cause organ failure.

2. Opus Genetics Inc. (NASDAQ:IRD)

6-Month Performance: 165.48%

Average Upside Potential: 83.05%

Opus Genetics Inc. (NASDAQ:IRD) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 6, Opus Genetics secured a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding and a $5 million equity investment. This capital infusion, combined with current resources, extends the company’s cash runway into 2029. The funding is designated to support the completion of pivotal studies for OPGx-LCA5 and OPGx-BEST1, initiate pre-launch commercial activities, and advance earlier-stage pipeline programs into clinical testing.

The agreement includes an upfront payment of $35 million in notes and a concurrent purchase of 1.1 million shares of common stock at $4.48 per share. Opus Genetics can access additional tranches of funding over the next 2 years based on clinical milestones, including the potential regulatory approval of its LCA5 program. The notes carry a 7-year maturity with a 6-year interest-only period, providing the financial flexibility to leverage the company’s gene therapy platform while maintaining a focus on inherited retinal diseases/IRDs.

With a strengthened balance sheet, Opus Genetics Inc. (NASDAQ:IRD) plans to transition three additional programs into the clinic over the next year: OPGx-RDH12, OPGx-MERTK, and OPGx-RHO. These programs target rare conditions that cause blindness and affect tens of thousands of patients globally. The company remains on track to report topline results from its Phase 1/2 trial of OPGx-BEST1 in mid-2026, marking a critical step toward restoring vision for patients with limited treatment options.

Opus Genetics Inc. (NASDAQ:IRD) is involved in the research and development of ophthalmic biopharmaceutical products, with a focus on the development and commercialization of therapies for the treatment of several eye disorders.

1. Erasca Inc. (NASDAQ:ERAS)

6-Month Performance: 303.05%

Average Upside Potential: 87.97%

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS molecular glue targeting solid tumors. In patients with non-small cell lung cancer, the therapy achieved a 62% response rate in late-line settings, rising to 75% for those previously treated with platinum therapies. Results for pancreatic cancer were also significant, showing a 50% response rate at the highest recommended dose of 32 mg daily.

The monotherapy was generally well-tolerated, with most side effects remaining low-grade and no treatment-related discontinuations reported. Pharmacokinetic data showed a steady, dose-dependent increase in exposure, effectively reducing tumor DNA across all tested patients at active dose levels. Early findings also suggest ERAS-0015 can be safely combined with standard treatments like panitumumab for colorectal cancer.

Following these results, the company has narrowed its timeline for disclosing additional expansion and combination cohort data to H1 2027. Monotherapy expansion and combination trials are already underway in the US and China. These milestones support the company’s efforts to position ERAS-0015 as a backbone therapy for a variety of RAS-mutant cancers.

Erasca Inc. (NASDAQ:ERAS) is a California-based clinical-stage precision oncology company that provides solutions for patients with RAS/MAPK pathway-driven cancers. The company’s core therapies include ERAS-0015, ERAS-4001, and ERAS-12.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.